Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

Alvotech ( (ALVO)) has provided an update. On December 31, 2025, Alvotech announced it had secured a new USD 100 million senior term loan facility maturing in December 2027, replacing its previous ...

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone health markets.

Dr Reddy's Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received a Complete Response Letter (CRL) from the USFDA for its Biologics License ...

New Delhi: Drug major Dr Reddy's Laboratories Limited's wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received a Complete Response Letter (CRL) from the United States Food and ...

Wellness shots are a quick way to get a boost of vitamins and nutrients. Ingredients like ginger and turmeric can help with inflammation and digestion. People taking blood-thinning medications may ...

Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo ...

BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership ...

Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...

Amneal Pharmaceuticals and mAbxience received Food and Drug Administration approval for two biosimilars. The companies said Monday that the FDA greenlit Biologics Licensing Applications for Boncresa, ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. Showing the work is the point. Aesthetics ...